CBS and cancer: Similar to AOAA, benserazide inhibits CBS through a PLP-dependent mechanism and in various cancer models, and produces the type of responses that would be expected from a CBS inhibitor in vitro and in vivo — although the required concentrations/doses are fairly high [274,275].